Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
immune globulin
Ultragenyx UK Limited
Multiple Sclerosis
1 trial -
immune globulin
Ultragenyx UK Limited
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
2 trials -
infigratinib 0.128 mg/kg/day
BridgeBio Oncology Therapeutics
Hypochondroplasia
1 trial -
innohep® 10.000 anti Xa IU/0,5mL PF.SYR. Ενέσιμο διάλυμα, innohep® 18.000 anti Xa IU/0,9mL PF.SYR. Ενέσιμο διάλυμα, innohep® 14.000 anti Xa IU/0,7mL PF.SYR. Ενέσιμο διάλυμα
The George Institute
Thromboprophylaxis in patients with advanced pancreatic cancer
1 trial -
interferon alfa
Ultragenyx UK Limited
Hepatitis C
1 trial -
levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets
Teva Pharma GmbH
Dysmenorrhea
2 trials -
linagliptine 5 mg
Boehringer Ingelheim
Diabetes Mellitus, Type 2
1 trial -
mRNA-4157, Saline solution for Placebo to v940 (mrna-4157), KEYTRUDA 25 mg/mL concentrate for solution for infusion
Merck Sharp and Dohme
Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
1 trial -
mannitol and microcrystalline cellulose, Tolebrutinib
Genzyme Europe B.V.
Primary Progressive Multiple Sclerosis
1 trial -
methotrexate
Ultragenyx UK Limited
Liver Cirrhosis, Biliary
1 trial -
methylprednisolone
Ultragenyx UK Limited
Spinal Cord Injury
1 trial -
metronomic adjuvant chemotherapy with capecitabine
Chongqing Claruvis Pharmaceutical Co.,
Nasopharyngeal Cancinoma (NPC)
1 trial -
mexiletine
Ultragenyx UK Limited
Pain
1 trial -
mycophenolate mofetil (CellCept)
Hoffmann-La Roche
Myasthenia Gravis, Generalized
1 trial -
nab-paclitaxel combined with carboplatin
The First People's Hospital of Lianyungang
Epithelial Ovarian Carcinoma Stage III
1 trial -
nexiguran ziclumeran
Regeneron UK Limited
Neuromuscular Disease
1 trial -
nintedanib, Nintedanib, nintedanib
Boehringer Ingelheim
Childhood Interstitial Lung Disease
1 trial -
non-pegylated liposomal doxorubicin
Teva Pharma GmbH
Tubular Breast Cancer Stage II
1 trial -
nonacog beta pegol
Novo Nordisk A/S
Congenital Bleeding Disorder
1 trial -
normal saline solution for infusion, Ociperlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tislelizumab, Ociperlimab
BeiGene
Locally advanced, unresectable, or metastatic non small cell lung cancer
1 trial -
novel stent
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Esophageal Cancer
1 trial -
obrixtamig
Boehringer Ingelheim
Small Cell Lung Cancer (SCLC)
1 trial -
paclitaxel
United Therapeutics Europe Ltd
Germ Cell Tumor
1 trial -
patients undergo cVATS segmentectomy
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer Stage I
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources